Trial Profile
A Phase IIa (Proof of Concept), Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of Oral Treatment With PBF-677 in Patients With Mild to Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs PBF 677 (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ADENOIBD
- Sponsors Palobiofarma
- 12 Jan 2022 Status changed from recruiting to completed.
- 18 Sep 2020 Planned End Date changed from 30 Dec 2020 to 30 Oct 2021.
- 18 Sep 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Aug 2021.